Emlőrák hasüregi áttétei – Egy szokatlan entitás klinikopatológiai jellemzői

Autor: András Drozgyik, F. Tamás Molnár, Zsófia Tokodi, György Bodoky, Dániel Kollár, Attila Oláh

Publikováno v: Magyar Sebészet. 75:265-269

EsetismertetésProgresszív gyomorürülési zavar miatt végeztünk műtétet egy hatvanöt éves nőbetegnél. A colon transversumot infiltráló irreszekábilis gyomordaganatot és peritoneális karcinózist észleltünk. Palliatív gasztro-jejuno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::072ea09c370a88f49590a1fca975eb0f
https://doi.org/10.1556/1046.2022.40003

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Autor: Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard Epstein, Paul Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall Tebbutt, Gerald Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp-Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean-Luc Van Laethem, Stéphanie Laurent, Neesha Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke Parner, Tapio Salminen, Leena-Maija Soveri, Eija Korkeila, Pia Osterlund, Julien Taieb, David Tougeron, Pascal Artru, François Xavier Caroli-Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus-Alexander Wörns, Holger Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balazs Juhasz, László Landherr, Tamas Pinter, György Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek Power, Luca Gianni, Salvatore Siena, Michele Milella, Alfredo Falcone, Rossana Berardi, Cinzia Bagalà, Francesco Di Costanzo, Fausto Roila, Andrea Ardizzoni, Evaristo Maiello, Silvia Fanello, Johanna Wilmink, Jan Willem de Groot, Geert Creemers, Eduardo Barroso, Tânia Rodrigues, Cristina Sarmento, Cheng Ean Chee, David Tai, Teresa Macarulla Mercade, Manuel Hidalgo Medina, Alfredo Carrato Mena, Joan Maurel Santasusana, Maria Jose Flor Oncala, Carlos Gomez Martin, Rafael Lopez, Andres Muñoz, Ruth Vera Garcia, Inmaculada Ales, Berta Laquente Sáez, Fernando Rivera, Javier Sastre, Cheng-Chung Wu, Yu-Wen Tien, De-Chuan Chan, Tsann-Long Hwang, Jeffry Evans, Jonathan Wadsley, Pippa Corrie, Andrew Biankin, Andrew Ko, Dana Cardin, Elena Chiorean, Johanna Bendell, Anne Noonan, Hedy Kindler, Nishan Fernando, Muhammad Beg, Thomas George, Marcus Noel, Noelle LoConte, Francis Arena, James Posey, Rajat Malhotra, Charles Lopez, Davendra Sohal, Robert McWilliams, Warren Brenner, Mark Womack, Rahul Seth, Renuka lyer, Nathan Bahary, Robert Marsh, Robert Ramirez, Cynthia Chua, James Reeves, Gulam Manji, Anthony El-Khoueiry, Robert Weaver, Vaibhav Sahai, Wells Messersmith, Robert Dreicer, Ahmed Zakari, Andrea Bullock, Benjamin Musher, Mitesh Borad, Edward Kim, David Bajor, Tim Huyck, Hassan Hatoum, Henry Xiong, Boris Pasche, Jill Lacy, Olugbenga Olowokure, Allen Cohn, Donald Richards, Robert Martin, Andrew Paulson, Paul Fanta, Smitha Krishnamurthi, Paul Oberstein, Jyotsna Fuloria

Publikováno v: Scientia

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192d001f322850ad486a84bac981c740
https://lirias.kuleuven.be/handle/20.500.12942/715374

Data from Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Autor: Charles S. Fuchs, David Ferry, Ling Gao, Allen S. Melemed, Lan Ni, Azhar Khan, Michael Heathman, Yanzhi Hsu, Kumari Chandrawansa, Howard Safran, Jiri Tomasek, Jaffer A. Ajani, Shuichi Hironaka, Yasuhiro Shimada, György Bodoky, Sang Cheul Oh, Eric Van Cutsem, Kei Muro, Atsushi Ohtsu, Josep Tabernero

Ramucirumab is an IgG1 monoclonal antibody specific for the vascular endothelial growth factor receptor-2. Ramucirumab, 8 mg/kg every 2 weeks, administered as monotherapy (REGARD) or in combination with paclitaxel (RAINBOW), was safe and effective in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa5b36e715805f8c083550fe760165db
https://doi.org/10.1158/1535-7163.c.6538746.v1

Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective

Autor: Miriam Koopman, Carmine Pinto, György Bodoky, Rocio Garcia-Carbonero, Francisca Marti Marti, Jean-Baptiste Bachet

Publikováno v: Future Oncology. 18:1313-1320

The PROMETCO study is collecting real-world data on metastatic colorectal cancer (mCRC) patients with two progressions. This international, prospective, longitudinal, observational cohort study is collecting data on mCRC patients with two disease pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc9eb22dd993decbf44eea8255a8731
https://doi.org/10.2217/fon-2021-1333

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

Autor: György Bodoky, Gabor Lakatos, Claus-Henning Köhne

Publikováno v: Cancer and Metastasis Reviews. 39:1143-1157

Colorectal cancer is a clinically and molecularly heterogeneous disease. Currently, extended RAS and BRAF mutation testing is obligatory in routine clinical practice before starting any treatment in the metastatic setting. Treatment decision making a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f95568ac5f4bfd8a0c342c0ad2c602
https://doi.org/10.1007/s10555-020-09913-7